Clinical Disease Activity With Long Term Natalizumab Treatment
Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to retrospectively investigate the proportion of
participants free of new or enlarging fluid-attenuated inversion recovery (FLAIR) lesions
over time in approximately 300 Relapsing-Remitting Multiple Sclerosis (RRMS) participants
with regular MRI follow-up, who have received natalizumab ≥24 month from two different
observational cohorts: 1) approximately 230 participants from the Czech Republic; and 2)
approximately 70 participants from Belgium. The secondary objectives of this study are as
follows: Brain volume change by various measures; Changes in the number and volume of
magnetic resonance imaging (MRI) lesions; No evidence of disease activity (NEDA) with and
without brain volume change.